Syneron Medical Ltd.  

(Public, NASDAQ:ELOS)   Watch this stock  
Find more results for elōs
10.94
-0.02 (-0.18%)
Real-time:   1:10PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.81 - 11.00
52 week 8.04 - 13.32
Open 11.00
Vol / Avg. 35,200.00/92,462.00
Mkt cap 400.74M
P/E     -
Div/yield     -
EPS -0.08
Shares 36.63M
Beta 1.34
Inst. own 73%
May 19, 2014
Q1 2014 Syneron Medical Ltd Earnings Release (Estimated) Add to calendar
Apr 17, 2014
Syneron Medical Ltd FDA Clearance of the UltraShape System Conference Call - Webcast
Mar 12, 2014
Syneron Medical Ltd at Barclays Healthcare Conference
Feb 20, 2014
Q4 & FY 2013 Syneron Medical Ltd Earnings Release
Feb 20, 2014
Q4 & FY 2013 Syneron Medical Ltd Earnings & New Star Lasers Inc Acquisition Conference Call - Webcast
Feb 13, 2014
Syneron Medical Ltd at Leerink Swann Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -2.04% -0.89%
Operating margin -1.80% -2.95%
EBITD margin - 2.05%
Return on average assets -1.67% -0.73%
Return on average equity -2.34% -0.59%
Employees 651 -
CDP Score - -

Address

Tavor Building 4, Industrial Zone P.O. Box 550
YOKNEAM, 20692
Israel
+972-4-9096200 (Phone)
+972-4-9096202 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Syneron Medical Ltd., designs, develops and markets aesthetic medical products based on its various technologies including its Electro-Optical Synergy (ELOS), technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. The Company�s products, which it sells primarily to physicians and other practitioners, target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin�s appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference and laser-assisted lipolysis. On February 13, 2012, the Company acquired Ultrashape Ltd. On March 14, 2012, Syneron acquired substantially all the assets of TransPharma Medical Ltd.

Officers and directors

Shimon Eckhouse Ph.D. Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Amit Meridor Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Hugo Goldman Chief Financial Officer
Age: 59
Bio & Compensation  - Reuters
Dominick A. Arena Director
Bio & Compensation  - Reuters
Stephen J. Fanning Director
Age: 61
Bio & Compensation  - Reuters
David Schlachet Director
Age: 68
Bio & Compensation  - Reuters
Michael J. Anghel External Independent Director
Age: 74
Bio & Compensation  - Reuters
Yaffa Krindel Independent Director
Age: 58
Bio & Compensation  - Reuters